PubRank
Search
About
Tarceva Italian Lung Optimization tRial (TAILOR)
Clinical Trial ID NCT00637910
PubWeight™ 82.56
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00637910
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med
2009
46.35
2
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst
1993
38.99
3
Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med
2005
31.48
4
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
N Engl J Med
2002
24.87
5
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
J Clin Oncol
2004
12.89
6
Cancer statistics, 2001.
CA Cancer J Clin
2001
11.73
7
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Lancet
2008
10.74
8
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
J Clin Oncol
2000
9.76
9
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst
2005
9.10
10
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol
2010
8.56
11
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol
2011
8.40
12
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
J Clin Oncol
2005
7.55
13
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
J Clin Oncol
2005
5.07
14
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
J Clin Oncol
2007
4.94
15
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
J Clin Oncol
2006
4.58
16
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
J Clin Oncol
2009
4.27
17
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
J Clin Oncol
2005
4.04
18
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Lancet Oncol
2013
4.04
19
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
J Clin Oncol
2011
3.73
20
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
J Natl Cancer Inst
2004
3.54
21
The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Eur J Cancer
1994
3.45
22
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
J Clin Oncol
2008
3.27
23
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
J Clin Oncol
2005
2.95
24
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Clin Cancer Res
2005
2.81
25
Ordinal regression models for epidemiologic data.
Am J Epidemiol
1989
2.62
26
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Clin Cancer Res
2010
2.48
27
Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
Nat Rev Clin Oncol
2010
2.26
28
Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
Eur J Cancer
2005
1.80
29
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Oncologist
2007
1.75
30
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Ann Oncol
2006
1.72
31
Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
J Clin Oncol
2005
1.42
32
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design.
J Pers Med
2014
0.92
33
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Oncotarget
2015
0.91
34
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Ann Oncol
2015
0.90
35
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.
J Thorac Dis
2013
0.90
36
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Clin Lung Cancer
2011
0.83
37
Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.
Curr Oncol
2012
0.81
38
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.
World J Clin Oncol
2013
0.79
39
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Ann Oncol
2011
0.79
40
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Sci Rep
2015
0.75
Next 100